Kilovoltage cone-beam computerized tomography ͑kV-CBCT͒ systems integrated into the gantry of linear accelerators can be used to acquire high-resolution volumetric images of the patient in the treatment position. Using on-line software and hardware, patient position can be determined accurately with a high degree of precision and, subsequently, set-up parameters can be adjusted to deliver the intended treatment. While the patient dose due to a single volumetric imaging acquisition is small compared to the therapy dose, repeated and daily image guidance procedures can lead to substantial dose to normal tissue. The dosimetric properties of a clinical CBCT system have been studied on an Elekta linear accelerator ͑Synergy ® RP, XVI system͒ and additional measurements performed on a laboratory system with identical geometry. Dose measurements were performed with an ion chamber and MOSFET detectors at the center, periphery, and surface of 30 and 16-cm-diam cylindrical shaped water phantoms, as a function of x-ray energy and longitudinal field-of-view ͑FOV͒ settings of 5,10,15, and 26 cm. The measurements were performed for full 360°CBCT acquisition as well as for half-rotation scans for 120 kVp beams using the 30-cm-diam phantom. The dose at the center and surface of the body phantom were determined to be 1.6 and 2.3 cGy for a typical imaging protocol, using full rotation scan, with a technique setting of 120 kVp and 660 mAs. The results of our measurements have been presented in terms of a dose conversion factor f CBCT , expressed in cGy/ R. These factors depend on beam quality and phantom size as well as on scan geometry and can be utilized to estimate dose for any arbitrary mAs setting and reference exposure rate of the x-ray tube at standard distance. The results demonstrate the opportunity to manipulate the scanning parameters to reduce the dose to the patient by employing lower energy ͑kVp͒ beams, smaller FOV, or by using half-rotation scan.
I. INTRODUCTION
With the introduction of advanced imaging technologies into the radiation therapy process such as: computerized tomography ͑CT͒ simulators, magnetic resonance imaging ͑MRI͒, and positron emission tomography, the ability to define target ͑GTV and CTV͒ and normal structures, as well as to assess the magnitude of internal organ motion has improved substantially. Exceptional advancements have also been made in the past decade in radiation treatment planning and delivery with the advent of intensity modulated radiation therapy ͑IMRT͒. With IMRT the prescribed dose can be delivered to the target volume with a high degree of conformality, while restricting dose to normal tissues. The full potential of these technologies in radiation treatment can be realized only if the patient can be positioned accurately and reproducibly during every session of the entire course of treatment delivery. Traditionally, the patient's treatment position is verified by acquiring orthogonal portal images ͑with films or electronic portal imaging devices͒ using megavoltage ͑MV͒ photon beams at the beginning of the treatment course or weekly. However, the precision of MV portal imaging is limited in defining the patient's position accurately due to the inherent low contrast and two-dimensional nature of the projection images. 1 To overcome these limitations the use of kilovoltage ͑kV͒ CT imaging systems in the treatment room are being investigated. [2] [3] [4] [5] [6] [7] [8] [9] The use of a conventional axial CT scanner in the treatment room has been described by a number of investigators. 2, [7] [8] [9] The availability of large area flat panel detectors have facilitated the development of integrated cone beam CT ͑CBCT͒ systems on linear accelerators. [3] [4] [5] [6] A kV-CBCT system has the potential of data acquisition and reconstruction of a large volumetric image in 1 to 2 min. 10 A kV-CBCT system can be used before every treatment session to localize a patient with high precision and, if necessary, set-up parameters such as patient position and beam geometry can be adapted for the intended treatment delivery. There is a growing interest in using kV-CBCT for high precision adaptive radiotherapy and several vendors have started development and commercialization of this technology.
In addition to the CBCT mode, an integrated kV system on a linear accelerator also provides radiographic and fluoroscopic modes of patient imaging. A kV imaging system, therefore, would provide the opportunity of imaging the patient position in two-dimensional radiographic mode or three-dimensional volume imaging mode before, during, and after the treatment session with a high degree of accuracy. 3 It is expected that these imaging modalities will facilitate advancement of high precision radiation treatments by providing accurate spatial information of patient position and, therefore, will be potentially used daily and repeatedly as an online image guidance tool. Although, the dose to the patient due to a kV image-guided RT session is small compared to that of the megavoltage treatment, repeated use of this modality for image guidance may contribute significant dose to normal tissue. Therefore, it is important to quantify the dose due to kV imaging of patients undergoing radiation therapy. In this report, the quantification of kV imaging dose for various imaging techniques is described. A method for estimating the dose delivered during imaging is presented to permit individual centers to document the doses used in their imaging procedures. The quantification of dose is an important first step toward developing guidelines for appropriate image-guidance use with respect to the potentially deleterious effects of additional dose.
II. MATERIALS AND METHODS
Two identical kV-CBCT systems were utilized for extensive measurements for this study. A limited set of measurements has also been made with a newly installed commercial system. The X-Ray Volume Imaging ͑XVI ® ͒ system, a clinical prototype, integrated with a medical linear accelerator, Synergy RP ͑Research Platform͒, manufactured by ELEKTA Oncology Systems, Norcross, GA, has been used to characterize the beams and also to make in vivo patient dose measurements. The XVI system consists of a conventional kV x-ray tube ͑Comet DX-9, Comet AG, Bern, Switzerland͒ mounted on a retractable arm onto the accelerator gantry's drum structure, in such a way that the central axes of the kV and MV beams intersects at the isocenter and are orthogonal to each other as shown in Fig. 1 . The x-ray tube is powered by a high-frequency generator ͑Medstone XHF-340, Fife, Scotland, UK͒ and operates in the range of 60-150 kVp. The image detection unit for the kV imaging is a flat panel amorphous silicon ͑Perkin Elmer Optoelectronics, Wiesbaden, Germany͒ detector with a dimension of 41 cm ϫ 41 cm mounted on a retractable arm at a distance of 153.6 cm from the source focal spot. In CBCT mode, the system can acquire projection data for complete rotation and reconstruct high-resolution volumetric images in about 1 to 2 min. 6 To facilitate the detailed measurements in water phantom a bench top imaging system was utilized. The bench top system ͑as shown in Fig. 2͒ consists of an x-ray tube, collimation system, and flat panel imager, which are identical to those of the XVI system. With the source at a fixed position, a turntable with its center coinciding with the central axis of the phantom can be set at 100 cm from the source and rotated around the vertical axis to simulate imaging geometry on the linear accelerator. For optimum image quality an added filtration of 2 mm Al and 0.1 cm Cu is used to harden the beam for all imaging protocols on the Synergy RP ® . The dosimetric measurements were therefore, performed with the added filtration both on the bench top and Synergy RP systems. The dose measurements were performed in readily available cylindrical shaped water phantoms made of 6-mm-thick Plexiglass ® . A 30-cm-diam phantom was used to simulate an average body while a 16 cm diameter was used for an average head. As shown in Fig. 3 , a specially designed jig allows accurate and arbitrary positioning of radiation detectors inside the water phantom in all three dimensions: radial distance r ͑equivalent depth d͒, angular position , and axis position z. However, all the data presented in this report have been measured for z = 0, along a plane coinciding with the central axis of the beam. A 0.6 cc Farmer type ionization chamber ͑NE-2571A͒ and Keithley 31614 electrometer, with air kerma calibration factor, N k , traceable to a standard dosimetry laboratory ͑NRCC, Ottawa͒ was used for measurements within the phantom. Dose was determined by methods recommended by AAPM report TG61. 11 A set of high sensitivity micro MOSFETs ͑Model 1002 RD, Thompson and Nielsen Inc., Ottawa, Canada͒, along with Autosense TM ͑Model number TN-RD-60͒ reader was used in high bias mode to measure dose on the surface of the phantom. The MOSFET calibration factors, in terms of cGy/ mV, were determined by measuring the response at a depth of 2.0 cm in water and comparing the corresponding dose measured by the ion chamber. An average calibration factor of 0.034 cGy/ mV ͑with a standard deviation of 0.0017 cGy/ mV͒ was determined for 100, 120, and 140 kVp beams.
To check the consistency of the doses measured on the bench top system, a limited set of measurements have been performed with a specially designed phantom on the Synergy RP as well as on a newly installed linear accelerator, Elekta Synergy ® . Synergy is equipped with a commercial XVI system and offers a set of similar, but slightly different scanning geometry to that used on the bench top and Synergy RP systems.
A. Characterization of the x-ray beams
The beam qualities were characterized by measuring the first half-value layers ͑HVL͒ of aluminum ͑99.99% pure͒ in narrow beam geometry. Attenuation measurements were performed in a 4 cmϫ 4 cm field with attenuator placed at a distance of 50 cm from the source and ion chamber ͑without build up cap͒ at 100 cm, while ensuring that no additional scattering medium was within 50 cm from the chamber.
The machine output was quantified, in terms of reference exposure rate ͑mR/ mAs͒ in air at the isocenter for 10 cm ϫ 10 cm field and relative output factors ͑ROF͒ for various field of views ͑FOV͒ and kVp settings, where ROF is defined as the ratio of the outputs for specified FOV and 10 cm ϫ 10 cm field. The linearity of output was also assessed as a function of total mAs settings, with various combinations of current ͑mA͒ and exposure time ͑ms͒ settings.
B. Single beam dosimetry in fluoroscopic mode
The dose values for a series of square static fields, as a function of depth along the central axis, were measured for both the cylindrical phantoms ͑i.e., 16 and 30 cm diameter͒ with a source to phantom axis distance of 100 cm. Although, in typical fluoro mode the beam exposure technique requires a few mAs, the dose measurements have been performed for a technique setting of 200 mAs for higher accuracy.
C. Dosimetry in CBCT mode
In CBCT mode, imaging data are typically acquired in our department with 330 projections ͑the maximum number of projections allowed on the Electa Synergy RP system͒ in a 360°͑full͒ rotation around the isocenter. As the size of the flat panel detector is 41 cmϫ 41 cm and is located at a fixed distance of 153.6 cm from the x-ray source, the maximum field of view in both lateral and longitudinal directions ͑FOV x , FOV z ͒ for data acquisition is restricted to approximately 26 cm, defined at the isocenter. To overcome this limitation of the lateral FOV x , an offset scanning geometry is used, 12 in which the imager is shifted laterally and a corresponding asymmetric beam, defined by an asymmetric colli- mator, is utilized to scan a larger FOV. As illustrated in Fig.  1͑b͒ , the effective scan diameter is twice the size of collimator opening, X1, and therefore the largest reconstructed volume may have a diameter of 52 cm ͑reconstructed FOV x ͒.
The offset geometry that is used most commonly, involves shifting the flat panel by approximately 10 cm, and utilizes an asymmetric collimator, defined by X1 = 19.5 cm, X2 = 6.5 cm, and Z = 26 cm at isocenter. In our clinical experience scanning various sites, including thoracic and abdominal regions, this offset geometry provided the optimum image sets, in terms of quality and reconstructed field of view. Unless otherwise stated, the dose values presented here have been measured with this asymmetric collimator geometry, i.e., with a reconstructed FOV x of 39 cm. Although, for the head phantom, a centered scanning geometry with smaller FOV x could have been used, for the convenience of keeping the same collimator settings and reconstruction algorithm the offset scanning geometry is used for all imaging procedures. The dose measurements have been made at various depths ͑d͒, with 330 projections and 2 mAs/ projection ͑as per our standard imaging protocol͒ for a number of FOV and kVp settings. To examine the linearity of dose as a function of total number of projections, while maintaining a constant mAs/ projections, measurements have been made using 100-600 projections. The dose values were measured using 120 kV beam and 2 mAs/ projection, at a depth of 2.0 cm and at the central axis of the 30-cm-diam cylindrical phantom for a FOV of 10 cmϫ 26 cm.
D. Formalism for dose estimation in CBCT mode
For a fixed scanning geometry and beam quality the dose at any point in phantom would be proportional to the total technique settings ͑mAs͒ and also to the in-air exposure rate at the reference point ͑e.g., isocenter͒. Since different x-ray tubes may have different exposure rates ͑mR/ mAs͒ and furthermore users may choose to use different numbers of projections and mAs/ projections, it would be more meaningful to present the measured dose data in terms of a dose conversion factor, e.g., dose per reference exposure rate at the isocenter. The relationship between dose to the phantom in CBCT mode and in-air reference exposure rate depends upon several factors such as; beam energy, phantom size, field of view, and location within the phantom. We introduce a term f CBCT to relate the dose and reference exposure rate using
where D CBCT is the dose ͑cGy͒ in phantom; E the beam energy ͑quality͒, expressed in HVL; R the radius of the phantom; d the depth in phantom; Ẋ Ref the exposure rate ͑R / mAs͒ for a reference field size ͑e.g., 10 cmϫ 10 cm͒; ROF the relative output factor for the FOV; f CBCT the dose conversion factor ͑cGy/ R͒ per complete rotation of CBCT acquisition as a function of phantom size ͑radius R͒, energy ͑E͒, field of view ͑FOV͒, and depth in phantom ͑d͒; T the total technique setting ͑mAs͒; product of tube current and time settings.
The results of the dose measurements are presented in terms of f CBCT as a function of depths for different beam energy, phantom size, and field of view. Given the reference exposure rate, technique setting, and imaging geometry one can estimate the dose to phantom using the above-noted equation and appropriate f CBCT values.
E. Validation of the dose estimation formalism

Doses in phantom
To test the performance of the dose estimation formalism, using the dose conversion factor, identical sets of measurements ͑using the same beam quality, technique settings͒ have been performed with 120 kV beam at a depth of 2.0 and 10 cm, as well as on the surface of a specially designed 20-cm-diam and 30-cm-long cylindrical solid water phantom, on the bench top system as well as on clinical systems ͑Synergy RP and Synergy͒. The FOV utlized for the bench top and Synergy RP was exactly identical, while for the Synergy system it was slightly different. The collimator cassette labeled M10 of Synergy system was utilized, which has a FOV x = 27.7 cm and FOV z = 13.5 cm. This collimator matches with the default setting of the imager arm, for which the center of the panel is offset by 11.5 cm from the central axis of the kV x-ray beams. Thus, the lateral field of view ͑at the isocenter͒ is defined by X1 = 20.2 cm and X2 = 7.5 cm and provides a reconstructed field of view, FOV x = 40.4 cm. The Synergy unit ͑commercial unit͒ was utilized in standard clinical mode, for which no added filtration was used. For proper dose consistency evaluation, the beam quality ͑HVL͒ as well as the appropriate in-air exposure rate was measured. The use of the solid water phantom facilitated the identical setup on the bench top as well as on the linear accelerators, with the exception that the phantom was supported by a 7.0-cm-block of Styrofoam ® for the measurements on linear accelerators, while on the bench top system there was no attenuating medium interfering the dose to the phantom. Based on the measurements from the bench top system, the values of f CBCT were derived and subsequently, using the appropriate in-air exposure rate, corresponding dose values were estimated for the clinical systems. The measured and estimated dose values for the clinical systems were then compared.
Patient skin dose
As a first-order approximation, a patient may be assumed to be water equivalent and cylindrical in geometry. To test the dose estimation formalism with this assumption, measurements have been performed on five patients undergoing CBCT in the abdominal and pelvic region using micro-MOSFETS. Four dosimeters were placed on the anterior skin surface ͑patient supine͒ along the iso-centric plane, approximately 40°apart. Three sets of measurements were performed for each patient. The skin dose was compared with the estimated dose based upon the X Ref
•
͑R / mAs͒, total mAs setting for the scan, and appropriate f CBCT for the surface.
III. RESULTS
As mentioned earlier, all the measurements performed in air as well as at depths in phantoms utilized a 0.6 cc ionization chamber and Kiethley electrometer. The surface dose measurements for phantoms and patients were performed with MOSFET dosimeters. The uncertainties of the ion chamber and MOSFET measurements were determined ͑standard deviation/ mean value͒ to be within ±0.5% and ±5%, respectively.
A. Beam characteristics
The qualities of 100, 120, and 140 kVp beams with added filtration of 2 mm Al and 0.1 mm of Cu were determined to be 6.9, 7.9, and 8.7 mm of HVL in Al, respectively. The in-air reference exposure rate ͑for 10 cmϫ 10 cm field͒ at the isocenter was measured to be 3.9, 6.5, and 9.5 mR/ mAs for 100, 120, and 140 kVp, respectively. The exposure rate was found to vary rapidly with increasing beam energy. The exposure rate relates to kVp settings with a second-order polynomial. The ROFs, measured at the isocenter for various field of views, with respect to the reference field, is shown in Fig. 4 . The ROF values increase rapidly initially with the increase of FOV, and however become less sensitive with field size beyond the FOV x of 10 cm.
The linearity of dose output has been determined, on both the XVI and bench top systems, by measuring the relative response of an ion chamber in a phantom with varying tube currents ͑mA͒, as well as exposure time ͑ms͒ independently. The relative output as a function of the product of current and exposure time settings ͑mA s͒ were found to be highly linear ͑R 2 = 0.9999͒.
B. Single beam dosimetry in fluoroscopic mode
The dose per mAs setting is presented as a function of depth for various square field sizes in Figs. 5 and 6. The depth dose varies significantly with field size due to increased scatter contribution at larger field sizes. On the other hand, the change in depth dose is small as a function of kVp setting. For a 10 cmϫ 10 cm field size, the dose at the center of 16 cm phantom is 38% and 42% of the surface doses for 100 and 120 kVp beams, respectively. While for the 30-cmdiam phantom the dose at the center of the phantom for the same field size is 14%, 16%, and 16% of the surface dose for 100, 120, and 140 kVp, respectively. For typical imaging protocols, a technique setting of 1 to 2 mA s is used and therefore the skin dose to phantom ranges from 0.1 to 0.4 mGy, depending upon the beam energy and phantom size.
C. Dose in CBCT mode
Dose measurements were made with complete rotation for a range of FOVs; from 5 cmϫ 26 cm up to 26 cmϫ 26 cm, The source to cylinder axis distance is set at 100 cm. The uncertainties of measurements on the surface and at depths are within ±5% and ±0.5%, respectively. using 330 projections at 2 mAs/ projection. Depending on the FOV, the maximum dose for the body phantom was found to vary from 1.8 to 2.3 cGy for 120 kVp and from 2.8 to 3.5 cGy for 140 kVp beams. For the head phantom, the maximum dose values were found to vary from 1.5 to 2.0 cGy for 100 kVp and from 2.6 to 3.4 cGy for 120 kVp beams. The dose data, at various depths and as a function of FOV, are shown in Tables I and II . It may be noted that the dose values at the surface are either very similar to or lower than those at 2.0 cm depth. This is mainly due to the nonoverlapping radiation exposure, resulting from scanning with asymmetric collimation of the FOV, as illustrated in the "white" region of Fig. 1͑b͒ . In this region, the dose is expected to be lower, as compared to that of scanning with centered geometry.
The relative dose values as a function of total number of projections is shown in Fig. 7 . As shown in the plot the dose in 30-cm-diam phantom is highly linear ͑R 2 = 0.995͒ with respect to the number of projections, in the range of 100-600 projections. This demonstrates that the dose values reported here can be scaled with the number of projections ͑e.g., for the Synergy system, in which 622 projections are acquired for full rotation scan͒, provided that the scanning geometry, phantom size, beam quality, and mAs/ projections are the same. ͑R / mAs͒, ROF, and total mAs setting to determine the dose to phantom.
D. Dose conversion factor in CBCT mode
E. Validation of the dose estimation formalism
Doses in phantom
The ratios of the doses measured at various depths of the 20-cm-diam solid water phantom, and to those estimated for the Synergy RP and Synergy systems are shown in Table III . The dose was estimated based on the f CBCT values derived from the corresponding measurements on the bench top system. In the case of Synergy, the HVL was measured to be 7.3 mm in Al and, therefore, the corresponding f CBCT value was determined by interpolation of the values measured on the bench top system. As shown, the dose values at depths agree within ±5%, but on the surface the dose differs by as much as 10%. The higher disagreement at surface may be partially due to larger uncertainties in MOSFET response as well as the dose perturbation ͑attenuation and scatter͒ from the Styrofoam support used during the measurements on linear accelerators.
Patient skin dose
The results of in vivo skin dose measurements ͑average and standard deviation͒ and corresponding dose estimation are shown in Table IV . Also, shown in Table IV are the patient anterior-posterior and lateral separations. However, the dose values were estimated based on the f CBCT values of 30-cm-diam water phantom and total mAs used for the imaging scan. The average discrepancies between the measured and estimated dose was found to be 0.08 cGy, with a maximum difference of 0.23 cGy.
IV. DISCUSSIONS A. Dose conversion factor and in vivo dose measurements
The dose conversion factor in CBCT mode, f CBCT , introduced in this report is a useful parameter which can be utilized readily to estimate patient dose, provided that the beam geometry, phantom size, and beam qualities are similar to those used here. The values of the factor depend significantly upon the phantom size due to the source to phantom distance as well as the attenuation characteristics of low energy photon beams. For a particular phantom size, however, the value of f CBCT varies slowly with the change in beam quality ͑HVL͒, as shown in Fig. 10 . For the 30-cm-diam phantom, at 15.0 cm depth, depending upon the FOV the value of f CBCT changes from 3 to 4% per 0.1 mm change in HVL of Al. While at a depth of 2.0 cm, the change ranges only from 0.4% to 0.9% for the same variation of HVL.
The average agreement between measured and estimated skin doses of five patients were found to be within ±5%, with a maximum deviation of 14%. The high standard deviation of measurements and magnitude of the maximum disagreement can be attributed to several factors, such as approximation of the patient as a homogeneous body phantom of 30 cm diameter, presence of couch in the beam path, and also uncertainty in MOSFET measurements. Further work is necessary, to address these issues for more accurate patient dose determination. Nevertheless, the present method of dose estimation may be considered acceptable, as a first-order approximation, in such a low dose environment. As pointed out earlier, the values of f CBCT presented here have been derived based on measurements on a bench top system. These values may not exactly reflect the dose values of a recently released commercial Elekta Synergy linear accelerator due to differences in the energy specifications and collimator geometry.
B. Total dose due to kV image guidance and comparison with MV imaging
The total dose to the patient due to kV image guidance can be put into perspective by comparing the dose due to conventional MV portal imaging. As an example, we consider that a patient receiving radiation therapy in the pelvic region will have 30 fractions of treatment and daily imaging will be performed for localization. First, let us consider the maximum dose per session due to ͑a͒ MV portal imaging with orthogonal pairs using 4 MU for each portal, ͑b͒ kV fluoroscopic imaging with orthogonal pairs using 120 kVp and 2 mAs/ field, and ͑c͒ kV CBCT with full rotation scan using 120 kVp and total of 660 mAs. The dose due to orthogonal MV portal imaging with a field size of 10 cm ϫ 10 cm was calculated in a 30-cm-diam phantom using PIN-NACLE Version 6.2b ͑Philips Medical System͒ and the maximum dose was determined to be 7 cGy. The maximum dose due to orthogonal pair of kV fluoroscopic fields on the same phantom is determined to be 0.25 mGy. Finally, the maximum dose per session of kV CBCT imaging is determined to be 2.3 cGy. It is obvious that the maximum doses due to kV fluoroscopic and CBCT imaging is lower by approximately a factor of 30 and 3, respectively, compared to that of MV portal imaging. However, for high precision adaptive radiation therapy it is expected that the kV imaging will be used at least once daily ͑may be even twice daily; before and after patient position adjustment͒ and, therefore, the total accumulated maximum dose may be in excess of 1 Gy. Moreover, the dose to patient due to CBCT will be distributed throughout a larger volume, as compared to conventional portal imaging. In the case of MV portal imaging, the additional dose can be easily added tothe overall dose distribution. However, because of its low energy and very low dose/fraction the imaging dose due to kV-CBCT may not be radiobiologically equivalent to MV dose [13] [14] [15] and therefore cannot be simply accounted for in the patient dose distribution. While the issue of dose accounting due to kV imaging needs further consideration, it is prudent, at a minimum, to accurately document the applied dose.
C. Dose reduction strategies
Although the dose due to image guidance with CBCT is small in the context of the uncertainty in therapy dose delivery, based upon ALARA principle, efforts should be made to minimize any unwanted dose to patients. The dose can be easily minimized by the following simple methods. These include ͑a͒ minimizing the overall technique settings ͑mAs͒ by reducing the number of projections and/ or reducing the mAs settings per projection, ͑b͒ by using lower kVp ͑beam energy͒, ͑c͒ minimizing the longitudinal field of view; FOV z to that necessary for image guidance. In addition to reducing patient dose, superior image contrast can be obtained due to the lower scatter component when using smaller FOV, 16 ͑d͒ by scanning the patient with partial rotation. The dose to patient on the opposite side of the source rotation can be reduced by a large factor. To examine the magnitude of the dose reduction due to half rotation scan, measurements have been made on the surface and at 2.0 cm depth around the circumference for the 30-cm-diam-phantom with half rotation plus the fan angle ͑194°͒ using 120 kVp beams. These measurements have been made with a symmetrical collimator setting, i.e., X1=13 cm and X2 = 13 cm. As shown in Fig.  11 the dose on the opposite side of the scan is approximately 15% of that on the source side. Further investigation of these "low dose" scanning methods is under way.
Depending upon the specific mode of image guidance with volumetric imaging, it may be possible to utilize several of the above-noted strategies to minimize patient dose. For example, if the bony landmark is to be used for patient localization, then a relatively low soft tissue discrimination image with lower beam energy and mAs settings ͑with reduced number of projections͒ can be utilized. On the other hand, if a high quality image ͑high tissue visibility͒ is desirable then a smaller cone angle can be used to minimize the dose and maximize image quality. The selection of these techniques will clearly depend on the objective and benefit of image guidance.
V. CONCLUSIONS
A comprehensive set of dose measurements has been performed for kV beams both in fluoroscopic and CBCT modes, using homogeneous cylindrical shaped body and head phantoms. The maximum dose to the phantom due to orthogonal fluoroscopic imaging, using 2 mAs exposure ranges from 0.1 to 0.4 mGy depending upon the beam energy and phantom size. The dose due to CBCT in a body phantom for a typical full rotation imaging protocol using 120 kVp beams, with a field of view of 26 cmϫ 26 cm and total technique settings of 660 mAs, ranges from 1.6 cGy ͑at the center͒ to 2.3 cGy ͑at surface͒. For similar geometry and mAs settings, the maximum dose to the phantom can be as high as 3.5 cGy when 140 kVp beams is used in the body phantom or 120 kVp is used for the head phantom. The results of our CBCT dose measurements using asymmetric collimator, as required for the offset imaging geometry, have been presented in terms of dose conversion factor, f CBCT ͑cGy/R͒. This factor depends upon beam energy, phantom size, and scanning geometry and can be utilized to estimate dose to homogeneous cylindrical phantoms for any arbitrary total mAs setting and reference exposure rate of the kVsource.
The measurements in homogeneous cylindrical water phantom will not simulate exactly the patient geometry and effects of anatomy ͑heterogeneity͒. However, the method presented here can be adequate for estimation and recording of patient dose due to kV fluoroscopic and CBCT imaging. It is clear from the results presented that there is a genuine opportunity to minimize the radiation dose penalty associated with image guidance by selecting geometry and exposure parameters that achieve the necessary image quality. This is an important first step to bringing proper assessment of the "dose penalties" associated with the benefits of imageguided radiotherapy.
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